RGEN:
Analysis & Opinions
-
January 10, 2013
The Medicines Company (MDCO) recently received good news with the company announcing positive results on its phase ...
-
January 09, 2013
Optimer Pharmaceuticals Inc. (OPTR) recently announced its preliminary sales for the fourth quarter and full year ...
-
January 09, 2013
Abbott Laboratories (ABT) recently announced that its Absorb Bioresorbable Vascular Scaffold (BVS) device has moved ...
-
January 08, 2013
Repligen Corporation (RGEN) recently joined forces with Pfizer, Inc. (PFE) for the advancement of its spinal ...
-
January 08, 2013
Aegerion Pharmaceuticals Inc. (AEGR) recently announced its 2013 guidance as the company prepares for the launch of ...
-
January 08, 2013
Alnylam Pharmaceuticals Inc (ALNY) recently announced its goal for the next two years (2013 and 2014) regarding its ...
-
January 07, 2013
AMAG Pharmaceuticals (AMAG) recently announced its preliminary fourth quarter 2012 financial results and its ...
-
January 07, 2013
Biotechnology company, BioMimetic Therapeutics, Inc. (BMTI) recently announced that it has started enrolling ...
-
January 04, 2013
Alkermes plc (ALKS) recently announced positive results from a phase I study on its new antipsychotic candidate, ...
-
January 03, 2013
Coronado Biosciences (CNDO) recently amended its existing license and supply agreements with Ovamed GmbH. Coronado ...
-
December 27, 2012
Dendreon Corporation (DNDN) recently sold its immunotherapy manufacturing facility (IMF) to Novartis Pharmaceuticals ...
-
December 27, 2012
AMAG Pharmaceuticals (AMAG) recently submitted a supplemental new drug application (sNDA) to the US Food and Drug ...
-
December 26, 2012
The US Food and Drug Administration (FDA) recently approved Aegerion Pharmaceuticals' (AEGR) Juxtapid (lomitapide) ...
-
December 26, 2012
Actelion (ALIOF) recently announced that it is moving forward with phase III development of cadazolid in patients ...
-
December 11, 2012
AMAG Pharmaceuticals (AMAG) recently presented new data on Feraheme from two pivotal phase III studies (IDA-301 and ...
-
June 28, 2012
Repligen Corporation (RGEN) recently announced that it received a complete response letter (CRL) from the U.S. Food ...
